We are live on
!
Find out more
GCM
Ghisallo Capital Management Portfolio holdings
AUM
$3.63B
1-Year Est. Return
30.51%
This Fund
S&P 500
This Quarter
Est. Return
-0.22%
1 Year Est. Return
+30.51%
3 Year Est. Return
+102.79%
5 Year Est. Return
+106.47%
10 Year Est. Return
–
AUM
$2.63B
AUM Growth
+$1.35M
(+0.05%)
Cap. Flow
+$154M
Cap. Flow
% of AUM
5.85%
Top 10 Holdings %
Top 10 Hldgs %
23.88%
Holding
517
New
128
Increased
23
Reduced
94
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coupang
CPNG
|
+$131M |
| 2 |
Sea Limited
SE
|
+$82.8M |
| 3 |
VICI Properties
VICI
|
+$61M |
| 4 |
Maravai LifeSciences
MRVI
|
+$57.7M |
| 5 |
Digital Realty Trust
DLR
|
+$48.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Keurig Dr Pepper
KDP
|
+$70.5M |
| 2 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$69.4M |
| 3 |
Guardant Health
GH
|
+$54.3M |
| 4 |
XPO
XPO
|
+$49M |
| 5 |
LAZR
Luminar Technologies
LAZR
|
+$43.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.23% |
| 2 | Financials | 19.42% |
| 3 | Consumer Discretionary | 18.8% |
| 4 | Healthcare | 10.16% |
| 5 | Real Estate | 7.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Oscar Health
OSCR
$8.43B
| $261K | 0.01% |
15,000
-235,000
| -94% | -$3.99M |
|
|
CNTA
427
DELISTED
Centessa Pharmaceuticals
CNTA
| $251K | 0.01% |
15,000
-10,000
| -40% | -$207K |
|
428
CVRx
CVRX
$64M
| $248K | 0.01% |
15,000
-11,000
| -42% | -$211K |
|
|
LENZ
429
LENZ Therapeutics
LENZ
$169M
| $246K | 0.01% |
2,143
-3,571
| -62% | -$529K |
|
430
Neuropace
NPCE
$512M
| $238K | 0.01% |
15,000
-34,999
| -70% | -$735K |
|
|
NUVL
431
DELISTED
Nuvalent
NUVL
| $226K | 0.01% |
+10,000
| New | +$290K |
|
432
Lyell Immunopharma
LYEL
$356M
| $222K | 0.01% |
750
-4,250
| -85% | -$1.27M |
|
|
TIGR
433
UP Fintech Holding
TIGR
$851M
| $212K | 0.01% |
20,000
-242,697
| -92% | -$3.81M |
|
|
AKYA
434
DELISTED
Akoya BioSciences
AKYA
| $209K | 0.01% |
15,000
-5,000
| -25% | -$83.6K |
|
|
TRML
435
DELISTED
Tourmaline Bio
TRML
| $203K | 0.01% |
1,500
+500
| +50% | +$68.5K |
|
|
AMAM
436
DELISTED
Ambrx Biopharma Inc
AMAM
| $203K | 0.01% |
15,000
-25,000
| -63% | -$450K |
|
437
Compass
COMP
$9.45B
| $199K | 0.01% |
15,000
-110,000
| -88% | -$1.58M |
|
|
ARYE
438
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| $198K | 0.01% |
+20,000
| New | +$199K |
|
|
ZY
439
DELISTED
Zymergen Inc. Common Stock
ZY
| $198K | 0.01% |
15,000
-17,612
| -54% | -$374K |
|
|
OMIC
440
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $168K | 0.01% |
500
+167
| +50% | +$85.6K |
|
|
ARYD
441
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $151K | 0.01% |
15,000
| – | – |
|
|
RERE
442
ATRenew
RERE
$970M
| $150K | 0.01% |
15,000
-115,000
| -88% | -$1.3M |
|
|
ZH
443
Zhihu
ZH
$285M
| $138K | 0.01% |
2,500
-97,500
| -98% | -$5.86M |
|
|
TUYA
444
Tuya Inc
TUYA
$1.12B
| $136K | 0.01% |
15,000
-485,000
| -97% | -$7.46M |
|
445
RxSight
RXST
$277M
| $127K | ﹤0.01% |
+10,000
| New | +$138K |
|
|
CNVY
446
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
| $126K | ﹤0.01% |
15,000
-185,000
| -93% | -$1.65M |
|
447
FTC Solar
FTCI
$46.6M
| $117K | ﹤0.01% |
1,500
-1,000
| -40% | -$101K |
|
|
DIDI
448
DELISTED
DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share
DIDI
| $117K | ﹤0.01% |
15,000
-1,485,000
| -99% | -$14M |
|
449
Absci
ABSI
$1.52B
| $116K | ﹤0.01% |
+10,000
| New | +$194K |
|
450
Sera Prognostics
SERA
$76.4M
| $111K | ﹤0.01% |
+10,000
| New | +$104K |
|
Similar funds
VI
ACM
SCM
OCM
SL
AA
GCM
MTIM
Ghisallo Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Ghisallo Capital Management held 517 positions worth $2.63B, up 0.05% from $2.63B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Ghisallo Capital Management deployed $154M of net new capital in Q3 2021, opening 128 new positions and adding to 23 existing holdings. Its largest new stake was Coupang: 3,786,356 shares worth $105M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was XPO, an estimated $49M trimmed.
- Ghisallo Capital Management's largest Q3 2021 buy was Coupang: 3,786,356 shares worth $105M.
- Ghisallo Capital Management added most to Maravai LifeSciences in Q3 2021, an estimated $57.7M increase.
- Ghisallo Capital Management's biggest Q3 2021 reduction was XPO, cutting an estimated $49M.
- Ghisallo Capital Management fully exited Keurig Dr Pepper in Q3 2021, selling an estimated $70.5M.
- Ghisallo Capital Management's ten largest holdings make up 24% of its $2.63B portfolio in Q3 2021.
- Ghisallo Capital Management opened 128 new positions and closed 61 in Q3 2021.
- Ghisallo Capital Management's portfolio value rose 0.05% quarter-over-quarter to $2.63B.
Based on Ghisallo Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.